LTC Gains Momentum as Thumzup Media Diversifies Crypto Portfolio with Major Investment
In a bold move signaling growing institutional confidence in digital assets, Thumzup Media has announced a $250 million treasury strategy to diversify its cryptocurrency holdings. The Nasdaq-listed company, previously focused on Bitcoin, will now allocate funds across XRP, Ethereum, Solana, Dogecoin, Litecoin (LTC), and USD Coin. This strategic pivot positions Thumzup at the forefront of institutional adoption of cryptocurrencies. The inclusion of Litecoin in this substantial investment highlights LTC's enduring relevance in the evolving crypto landscape. As of July 2025, this development underscores the maturing cryptocurrency market where established altcoins like Litecoin continue to attract significant institutional capital alongside market leaders Bitcoin and Ethereum.
Thumzup Media Diversifies Crypto Holdings with $250M Investment in XRP, Bitcoin, and Ethereum
Thumzup Media, a Nasdaq-listed company, has approved a $250 million treasury strategy to expand its cryptocurrency holdings beyond Bitcoin. The firm will now allocate funds across XRP, Ethereum, Solana, Dogecoin, Litecoin, and USD Coin, marking a strategic pivot toward diversified digital asset exposure.
CEO Robert Steele framed the move as positioning the company at the forefront of institutional crypto adoption. Thumzup's existing 19 Bitcoin holdings, valued at $2.26 million, represent just 0.9% of the new allocation cap - signaling aggressive expansion into altcoins.
The decision reflects growing corporate confidence in crypto assets amid evolving U.S. regulatory clarity. By broadening its treasury strategy, Thumzup joins a wave of public companies hedging traditional cash reserves with digital assets.
MEI Pharma Surges 33% After $100M Litecoin Treasury Allocation
MEI Pharma's stock soared 33% intraday following its unprecedented $100 million pivot to Litecoin as a primary treasury asset. The biotech firm's shares peaked above $9.00 before settling near $6.02, marking one of the most dramatic crypto-linked equity moves in the healthcare sector.
The strategic shift includes a $100 million private placement led by Litecoin creator Charlie Lee and market Maker GSR. MEI will issue 29 million shares at $3.42 each through Titan Partners Group, with the transaction structured to bypass SEC registration under Regulation D exemptions.
This treasury overhaul positions Litecoin at the center of MEI's financial strategy, challenging conventional biotech capital management practices. The deal's closing is anticipated by July 2025, contingent on standard regulatory approvals.
MEI Pharma Unveils $100M Litecoin Treasury, Becomes First Public Firm To Hold LTC As Reserve
MEI Pharma has secured a $100 million private investment at $3.42 per share, signaling a strategic pivot toward cryptocurrency adoption. The biotech firm will allocate the capital to a Litecoin treasury reserve, marking the first instance of a public company holding LTC as a reserve asset. Charlie Lee, Litecoin's creator, joins MEI's board as part of the deal, replacing Taheer Datoo.
GSR has been appointed as MEI's digital asset advisor to oversee the Litecoin Treasury Strategy, blending biotech and blockchain expertise. The funding round attracted participation from the Litecoin Foundation and prominent crypto investors including MOZAYYX, ParaFi, and CoinFund. Litecoin's 14-year operational history and dominance in payment processing platforms like BitPay positioned it as MEI's choice for a decentralized treasury asset.
"This institutional endorsement accelerates Litecoin's penetration into traditional capital markets," Lee stated. The partnership underscores LTC's utility in global transactions, remittances, and retail payments—a validation of its 'digital silver' narrative against Bitcoin's Gold standard.
